Gelteq Limited Stock Price, News & Analysis

Healthy Extracts (OTCQB:HYEX) has launched two groundbreaking wellness products in North America: Hydrate EZ™ and Mynus Sugar™, featuring Gelteq's (NASDAQ:GELS) proprietary gel-based delivery system. Both products come in innovative 2-oz gel packs with no mixing required.

The company reported 20% revenue growth in H1 2025 and recently completed a transformative merger with Gummy USA, which is expected to accelerate growth by over 50%. The new products target significant market opportunities, with the hydration supplement market projected to reach $4.4 billion by 2034 and the carb blocker market expected to hit $2.5 billion by 2033.

The launch follows a distribution agreement with Gelteq announced in June, establishing HYEX as the operational backbone for Gelteq's products in North America. Products are available through Bergametna.com and Amazon, with promotional discounts of up to 20% for subscribers.

Gelteq (GELS) has signed a memorandum of understanding with IDT Australia (ASX: IDT) to establish a dedicated manufacturing facility for its gel-based products. The partnership aims to support the development and scale-up of Gelteq's proprietary gel-based oral delivery platform across pharmaceutical, nutraceutical, and animal health markets.

IDT Australia brings over 50 years of pharmaceutical manufacturing expertise and capabilities in cGMP manufacturing, FDA and TGA approved laboratory testing, and clinical packaging. The agreement includes dedicated facilities, equipment, trained staff, operational support, and necessary regulatory compliance certifications from APVMA, FDA, and TGA.

Gelteq Limited (NASDAQ: GELS) has announced a strategic expansion in North America through an exclusive logistics and distribution agreement with Healthy Extracts (OTCQB: HYEX). Under the partnership, Healthy Extracts will serve as Gelteq's exclusive North American fulfillment partner, managing all product receiving, warehousing, inventory, and order fulfillment from its Henderson, Nevada facility. The collaboration aims to accelerate Gelteq's distribution of gel-based delivery solutions across the United States and Canada while reducing costs and improving operational efficiency. The agreement follows an earlier purchase order from Healthy Extracts for Gelteq products and is expected to enable market distribution by Q3 2025. Both companies anticipate enhanced margin efficiencies, faster delivery times, and new revenue growth opportunities through this vertically aligned partnership.

Gelteq (NASDAQ: GELS) announces that its brand Sportsgel has become the official sponsor of the Professional Pickleball Tour and League of Australia and New Zealand. The three-year sponsorship agreement grants Gelteq exclusivity for consumable performance, health, recovery, and sports-related gels with both PPAA and MLPA.

The partnership includes on-court branding at all PPAA and MLPA events, team apparel branding, and presence across social and digital platforms. The leagues feature prominent owners including former World No.1 golfer Adam Scott, NBA Star Patty Mills, five-time Olympian Nat Cook, and cricketer Steve Smith.

The collaboration aims to develop tailored, league-branded products specifically designed for pickleball players, leveraging Gelteq's gel-based delivery platform and the expertise of their new Head of Sports Performance, Matthew Jones.

Gelteq (NASDAQ: GELS) has announced the launch of its SportsGel brand and secured a distribution agreement with WPIC Marketing and Technologies for the Asia-Pacific region. The company's first market entry will be in China during H1 2025, targeting the country's sports nutrition market, valued at $6.5 billion in 2022 with a projected annual growth rate of 9.1% until 2027.

SportsGel will initially launch sports-specific gels for running and cycling, along with a functional hydration product. The brand aims to provide improved sports performance solutions without compromising taste, mouthfeel, and convenience. Matthew Jones, Gelteq's Head of Sports Performance, will oversee all SportsGel formulations, which will be available for licensing to companies interested in Gelteq's proprietary delivery system.

Gelteq (NASDAQ: GELS) has appointed Matthew Jones as Head of Sports Performance to oversee the growth, outreach, and customer strategy of its sports vertical. Jones, an internationally-experienced sports dietitian, currently serves as Head of Nutrition with the UAE Football Association and consults for the Boston Celtics.

Jones brings over 12 years of elite sports experience, including work in international football, English Premier League, Women's Super League, and NCAA Division I sports. He holds a Master's Degree in Nutrition Science from University of Chester and is registered with the British Dietetic Association, Sport Nutrition Register.

The appointment aligns with Gelteq's strategy to expand its ingestible gel technology in sports nutrition, leveraging its unique formulation for improved nutrient delivery compared to traditional methods.

Gelteq (NASDAQ: GELS) has appointed Dr. Paul Wynne as its new Chief Scientific Officer (CSO). Dr. Wynne brings over 35 years of experience in analytical chemistry, advanced materials, drug metabolism, pharmaceutical formulation, and drug delivery. Prior to joining Gelteq, he served as Manager of the Medicines Manufacturing Innovation Centre at Monash University for eight years.

In his new role, Dr. Wynne will oversee product and formulation strategies, lead the scientific team's growth, manage the company's intellectual property portfolio, and coordinate with manufacturing partners. His expertise includes authoring over 80 peer-reviewed papers and 120 industry presentations. He holds multiple advanced degrees from RMIT University, including a PhD in Chemistry and Toxicology.

Gelteq (NASDAQ: GELS) has received FDA approval for its suitability petition for a new animal drug development, marking its entry into the animal pharmaceuticals market. The approval enables a fast-track pathway through an abbreviated new animal drug application (ANADA) for converting an existing FDA-approved generic animal drug from pill form to an oral gel form using Gelteq's ingestible gel platform.

The FDA's approval under section 512(n)(3)(C) of the FD&C Act eliminates the need for additional safety and effectiveness studies, potentially reducing the timeframe for final drug approval. However, the company notes that this suitability petition approval does not guarantee final ANADA approval for the proposed generic new animal drug.

Gelteq (NASDAQ: GELS), a company specializing in gel-based delivery solutions for various products including prescription drugs and pet care, has announced its participation in the Benchmark Company 13th Annual Discovery Investor Conference. The event will take place on December 11, 2024, at the New York Athletic Club in New York City.

Co-Founders Nathan Givoni (CEO) and Simon Szewach (Executive Chairman) will be available for one-on-one meetings with analysts and investors throughout the conference day. Interested attendees can arrange meetings through their Benchmark Company representative.